Pfizer is packing up its South San Francisco research and office campus at 181 Oyster Point Boulevard by the end of April, stepping back from one of the Peninsula’s best-known lab clusters. The company says the site is underused, and employees tied to the campus will shift into remote roles instead of moving to another local office. The move trims Pfizer’s Bay Area footprint and adds its name to the growing list of big players rethinking how much lab space they really need around here.
Pfizer confirms closure after sublease push
Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for sublease, according to the San Francisco Chronicle. Company spokesperson Jerica Pitts told the paper the office is “currently underutilized” and stressed that Pfizer will continue to maintain a presence elsewhere in California even as it exits this particular site.
Staffing and past cuts
California’s Employment Development Department told SFGATE that Pfizer has not filed any WARN layoff notices tied to the South San Francisco campus. Instead, Pfizer has said that employees designated to the site will transition to remote roles. The location has already been through one round of cuts this year: the company eliminated about 52 positions there in 2024, according to FiercePharma.
What it means for Oyster Point and landlords
The site sits inside the Cove at Oyster Point, a multibuilding lab-and-office campus where brokers say big chunks of space have become tougher to fill. Local brokers have pegged vacancy in the submarket at close to 30 percent, with landlords sweetening deals with hefty concessions to get tenants in the door, the San Francisco Chronicle reported.
How the site got here
Pfizer picked up the Oyster Point property when it acquired Global Blood Therapeutics in October 2022 for about $5.4 billion, according to Pfizer. That deal brought GBT’s sickle-cell portfolio under Pfizer’s umbrella, along with GBT’s former headquarters at the South San Francisco campus.
Why this matters
Oyster Point is not exactly a ghost town. UCSF Health recently made a major commitment to the area, inking a lease for roughly 280,000 square feet at Kilroy’s Oyster Point Phase 2 in January, a sign the submarket can still land heavyweight institutional tenants, as reported by Hoodline. Whether landlords can quickly turn Pfizer’s large block of lab space into another long-term deal will be an early stress test of how resilient the Oyster Point lab scene really is in the months ahead.
